Buprenorphine Available at 39.4 Percent of U.S. Pharmacies in 2023
WEDNESDAY, Sept. 3, 2025 -- From 2017 to 2023, there was an increase in buprenorphine availability overall, reaching 39.4 percent in 2023, according to a study published online Sept. 2 in Health Affairs.
Jenny S. Guadamuz, Ph.D., from the University of California Berkeley, and colleagues examined trends in the availability of buprenorphine at U.S. retail pharmacies in 2017 to 2023. Pharmacies with buprenorphine availability were defined as those that dispensed at least one prescription of buprenorphine each month in a given year.
The researchers found an increase in the availability of buprenorphine from 33.1 percent of pharmacies in 2017 to 39.4 percent of pharmacies in 2023. Increases were seen across all neighborhood types; pharmacies located in Black and Latinx neighborhoods were less likely to dispense buprenorphine than those serving White or diverse neighborhoods (17.8 and 16.5 percent, respectively, versus 45.8 and 30.9 percent, respectively, in 2023). Buprenorphine availability increased in most states, but declined significantly in Washington, D.C., and in five states between 2017 and 2023. In nearly all states, availability was lowest in Black and Latinx neighborhoods.
"If policymakers fail to introduce policies that increase equitable access to buprenorphine at local pharmacies, existing racial and ethnic disparities in opioid use disorder treatment and recovery will likely worsen," Guadamuz said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Receipt of Meds for Opioid Use Disorder in Jail Increases Use After Release
TUESDAY, Sept. 23, 2025 -- Receipt of medications for opioid use disorder (MOUD) in jail is associated with an increased likelihood of receiving MOUD after community release...
High Exposure to Prenatal Prescribed Opioid Analgesics Likely Not Associated With ASD Risk
THURSDAY, Sept. 18, 2025 -- Associations are observed between high exposure to prescribed opioid analgesics (POAs) and the risk for autism spectrum disorder (ASD) or...
Over-the-Counter Naloxone Shows Limited Uptake
WEDNESDAY, Sept. 17, 2025 -- Sales of over-the-counter (OTC) naloxone increased in the United States after it was made available to the public then quickly declined...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.